Tower Research Capital LLC TRC Grows Holdings in Edwards Lifesciences Co. (NYSE:EW)

Tower Research Capital LLC TRC lifted its position in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 67.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 49,914 shares of the medical research company's stock after purchasing an additional 20,069 shares during the quarter. Tower Research Capital LLC TRC's holdings in Edwards Lifesciences were worth $3,695,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in EW. Virtu Financial LLC acquired a new stake in shares of Edwards Lifesciences during the third quarter worth about $3,173,000. World Investment Advisors LLC raised its stake in Edwards Lifesciences by 1,660.7% during the 3rd quarter. World Investment Advisors LLC now owns 72,277 shares of the medical research company's stock valued at $4,770,000 after acquiring an additional 68,172 shares during the last quarter. Wilmington Savings Fund Society FSB lifted its position in Edwards Lifesciences by 147.0% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 9,106 shares of the medical research company's stock worth $601,000 after acquiring an additional 5,420 shares during the period. Destination Wealth Management grew its stake in shares of Edwards Lifesciences by 2.8% in the 3rd quarter. Destination Wealth Management now owns 7,012 shares of the medical research company's stock valued at $463,000 after purchasing an additional 193 shares during the last quarter. Finally, Tidal Investments LLC increased its holdings in shares of Edwards Lifesciences by 0.7% in the third quarter. Tidal Investments LLC now owns 39,532 shares of the medical research company's stock valued at $2,609,000 after purchasing an additional 275 shares during the period. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Trading Up 6.7 %

Shares of EW stock traded up $4.69 on Thursday, reaching $75.15. 11,705,304 shares of the stock were exchanged, compared to its average volume of 4,982,174. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $95.25. The stock has a market cap of $44.18 billion, a P/E ratio of 10.78, a price-to-earnings-growth ratio of 4.82 and a beta of 1.15. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The firm has a 50 day moving average of $70.93 and a two-hundred day moving average of $71.02.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The company had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.40 billion. During the same period last year, the business posted $0.66 EPS. On average, research analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 6,500 shares of the business's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $75.75, for a total transaction of $492,375.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at $3,555,402. The trade was a 12.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the sale, the chief financial officer now owns 30,561 shares of the company's stock, valued at approximately $2,315,301.36. This trade represents a 26.91 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 71,853 shares of company stock worth $5,163,062 over the last ninety days. 0.34% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

EW has been the subject of several recent research reports. Canaccord Genuity Group increased their price target on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a "hold" rating in a report on Thursday, February 13th. Barclays lifted their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. Piper Sandler raised shares of Edwards Lifesciences from a "neutral" rating to an "overweight" rating and increased their price target for the stock from $73.00 to $80.00 in a report on Thursday. Truist Financial lowered their price objective on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a report on Friday, April 11th. Finally, Wolfe Research cut Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences has an average rating of "Hold" and an average price target of $79.25.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.